{"filing":{"accession_number":"0001104659-26-106567","cik":"0001583107","ticker":"TBPH","company_name":"Theravance Biopharma, Inc.","form":"8-K","filing_date":"2026-09-10","report_date":"2026-09-10","primary_document":"tm2624960d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465926106567/tm2624960d1_8k.htm"},"events":[{"id":32578,"run_id":29936,"accession_number":"0001104659-26-106567","anchor_item_number":"8.01","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"summary":"The filing discloses three shareholder complaints and thirteen demand letters filed in connection with the pending Zymeworks merger, alleging disclosure deficiencies in the proxy statement and seeking to enjoin or rescind the transaction. While the company denies merit and voluntarily supplements disclosures to minimize litigation burden, the existence of multiple coordinated legal challenges to a material M\u0026A transaction constitutes material litigation that would affect a reasonable investor's assessment of deal risk and timing.","company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","filing_date":"2026-09-10","form":"8-K","submitted_at":null,"items":[{"id":35780,"accession_number":"0001104659-26-106567","item_number":"8.01","item_title":"Other Events.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"The filing discloses three shareholder complaints and thirteen demand letters filed in connection with the pending Zymeworks merger, alleging disclosure deficiencies in the proxy statement and seeking to enjoin or rescind the transaction. While the company denies merit and voluntarily supplements disclosures to minimize litigation burden, the existence of multiple coordinated legal challenges to a material M\u0026A transaction constitutes material litigation that would affect a reasonable investor's assessment of deal risk and timing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T13:11:43.580868+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35780,"accession_number":"0001104659-26-106567","item_number":"8.01","item_title":"Other Events.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"The filing discloses three shareholder complaints and thirteen demand letters filed in connection with the pending Zymeworks merger, alleging disclosure deficiencies in the proxy statement and seeking to enjoin or rescind the transaction. While the company denies merit and voluntarily supplements disclosures to minimize litigation burden, the existence of multiple coordinated legal challenges to a material M\u0026A transaction constitutes material litigation that would affect a reasonable investor's assessment of deal risk and timing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T13:11:43.580868+00:00","company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","filing_date":"2026-09-10"}]}